Allogeneic mesenchymal stem cell compositions and methods thereof

A cryopreserved pharmaceutical composition comprising pooled and cultured Mesenchymal Stem Cells (MSCs), Human Serum Albumin (HSA), Multiple Electrolytes Injection, Type I, USP, and Dimethyl Sulphoxide (DMSO), prepared by the method comprising:

• a) creating 3 or more master cell banks and cryopreserving the master cell banks, wherein each master cell bank is created from MSCs from an individual donor cultured to passage 1 (P1);
• b) thawing the 3 or more master cell banks and pooling MSCs from the 3 or more master cell banks, followed by culturing the pooled MSCs to passage 2 (P2);
• c) culturing the pooled MSCs to passage 3 (P3) to create a working cell bank comprising pooled and cultured MSCs, followed by cryopreserving the working cell bank;
• d) thawing the working cell bank and further culturing said pooled and cultured MSCs to passage 4 (P4) and subsequently to passage (P5);
• and
• e) cryopreserving the pooled and cultured MSCs after d) to obtain the cryopreserved pharmaceutical composition,
• wherein the pooled and cultured MSCs in the cryopreserved pharmaceutical composition have a concentration ranging from about 25 million to 200 million cells, the HSA has a concentration ranging from about 1% to 6%, the Multiple Electrolytes Injection, Type I, USP has a concentration ranging from about 80% to 90%, and the DMSO has a concentration ranging from about 5% to 10%;
• and wherein the pooled and cultured MSCs after P5 have increased cytokine secretion compared to the pooled and cultured MSCs after P3.